Results 91 to 100 of about 7,835,088 (297)

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Rich schools, poor schools

, 2015
sponsorship: Policy Research Centre on Study and School Careers (steunpunt SSL) financed by the Ministry of the Flemish Government (Belgium). The conclusions of the article do not necessarily reflect the views of (and do not commit) the financing body.
Poesen-Vandeputte, Mayke, Nicaise, Ides
openaire   +1 more source

Investigation of Relationship between Sources of Selfefficacy Beliefs of Secondary School Students and Some Variables

, 2013
Ali Arslan
openalex   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

Speaking Problems of 9 th Grade High School Turkish Learners of L2 English and Possible Reasons for those Problems: Exploring the Teachers and Students’ Perspectives

, 2014
Fatma Tokoz Goktepe
openalex   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Conditions limiting the inclusion of migrant children in the school environment

Educazione Interculturale
This article addresses a contemporary phenomenon of deep concern: the educational integration of migrant children in school environments, derived from geopolitical situations, specifically in countries such as Venezuela.
Carlos Iván García Suárez, Yamileth Bolaños, Susy Yarley Hinestroza Rodríguez   +2 more
doaj   +1 more source

Teaching critical thinking about health information and choices in secondary schools: human-centred design of digital resources [PDF]

Sarah Rosenbaum, Jenny Moberg, Faith Chesire, Michael Mugisha, Ronald Ssenyonga, Marlyn Ochieng, Clarisse Marie Claudine Simbi, Esther Nakyejwe, Benson Ngatia, Gabriel Rada, Juan Vásquez-Laval, José Damián Garrido, Grace Baguma, Sam Kuloba, Edward Sebukyu, Richard Kabanda, Irene Mwenyango, Tonny Muzaale, Pamela Nandi, Jane Njue, Cyril Oyuga, Florian Rutiyomba, Felecien Rugengamanzi, Joan Murungi, Allen Nsangi, Daniel Semakula, Margaret Kaseje, Nelson K. Sewankambo, Laetitia Nyirazinyoye, Simon Lewin, Andrew D Oxman, Matt Oxman   +31 more
openalex   +1 more source